An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder
- 13 March 2018
- journal article
- research article
- Published by Springer Nature in Journal of Autism and Developmental Disorders
- Vol. 48 (8) , 2748-2757
Abstract
Nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR, are implicated in the pathophysiology of both autism spectrum disorder (ASD) and aggressive behavior. We explored the feasibility, tolerability, and preliminary efficacy of targeting nAChRs using transdermal nicotine to reduce aggressive symptoms in adults with ASD. Eight subjects were randomized in a double-blind crossover trial of 7 mg transdermal nicotine or placebo, each for 1 week. All participants tolerated nicotine treatment well. Five subjects contributed data to the primary outcome, Aberrant Behavior Checklist-Irritability (ABC-I) subscale change from baseline, which was improved by nicotine compared to placebo. Sleep ratings were also improved by nicotine and correlated with ABC-I improvement. These findings support further investigation of nAChR agonists for aggression and sleep in ASD.Keywords
Funding Information
- Autism Speaks (9699)
- National Institute on Drug Abuse (R01DA14241)
- National Institute of Mental Health (R01MH077681, R25MH071584, T32MH019961, T32MH14276)
- American Academy of Child and Adolescent Psychiatry (Pilot Award for General Psychiatry Residents)
- Child Study Center, Yale School of Medicine (Child Study Center Associates)
This publication has 48 references indexed in Scilit:
- Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum DisordersJournal of Child and Adolescent Psychopharmacology, 2012
- Nicotine treatment of mild cognitive impairmentNeurology, 2012
- An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutantsBiochemical Pharmacology, 2011
- Pharmaco-genetically guided treatment of recurrent rage outbursts in an adult male with 15q13.3 deletion syndromeAmerican Journal of Medical Genetics Part A, 2011
- Delineation of 15q13.3 microdeletionsClinical Genetics, 2010
- Normalizing Effects of Modafinil on Sleep in Chronic Cocaine UsersAmerican Journal of Psychiatry, 2010
- A small recurrent deletion within 15q13.3 is associated with a range of neurodevelopmental phenotypesNature Genetics, 2009
- It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and moodProgress in Neurobiology, 2008
- A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizuresNature Genetics, 2008
- Distribution of Nicotinic Receptors in the Human Hippocampus and ThalamusEuropean Journal of Neuroscience, 1994